Last reviewed · How we verify
anti-GD2-800CW — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
anti-GD2-800CW (anti-GD2-800CW) — Princess Maxima Center for Pediatric Oncology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-GD2-800CW TARGET | anti-GD2-800CW | Princess Maxima Center for Pediatric Oncology | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-GD2-800CW CI watch — RSS
- anti-GD2-800CW CI watch — Atom
- anti-GD2-800CW CI watch — JSON
- anti-GD2-800CW alone — RSS
Cite this brief
Drug Landscape (2026). anti-GD2-800CW — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-gd2-800cw. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab